Skip to main content
. 2015 Jul 7;171(3):344–354. doi: 10.1111/bjh.13582

Table 2.

Agents commonly received (≥10% of patients overall) as part of subsequent therapy following VTD or VTDC

Agent VTD (= 49) VTDC (= 49)
n % n %
Any subsequent therapy 24 49 28 57
Dexamethasone 20 41 21 43
Lenalidomide 17 35 16 33
Bortezomib 15 31 16 33
Thalidomide 9 18 8 16
Cyclophosphamide 6 12 10 20
Melphalan 3 6 8 16
Doxorubicin 4 8 6 12

VTD, bortezomib‐thalidomide‐dexamethasone; VTDC, bortezomib‐thalidomide‐dexamethasone plus cyclophosphamide.